200,000+ products from a single source!
sales@angenechem.com
184036-34-8 | N-(4-chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d][1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide
CAS No: 184036-34-8 Catalog No: AG0039V5 MDL No:
Product Description
Catalog Number:
AG0039V5
Chemical Name:
N-(4-chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d][1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide
CAS Number:
184036-34-8
Molecular Formula:
C18H15ClN2O6S2
Molecular Weight:
454.9045
IUPAC Name:
N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
InChI:
InChI=1S/C18H15ClN2O6S2/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h3-5,7,21H,6,8H2,1-2H3
InChI Key:
PHWXUGHIIBDVKD-UHFFFAOYSA-N
SMILES:
O=C(c1sccc1S(=O)(=O)Nc1onc(c1Cl)C)Cc1cc2OCOc2cc1C
UNII:
J9QH779MEM
Properties
Complexity:
720
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
454.006g/mol
Formal Charge:
0
Heavy Atom Count:
29
Hydrogen Bond Acceptor Count:
9
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
454.896g/mol
Monoisotopic Mass:
454.006g/mol
Rotatable Bond Count:
6
Topological Polar Surface Area:
144A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.7
Literature
| Title | Journal |
|---|---|
| Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. | Journal of applied toxicology : JAT 20160101 |
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | Toxicological sciences : an official journal of the Society of Toxicology 20131101 |
| Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. | Chemical research in toxicology 20130617 |
| What is the best method of proteinuria measurement in clinical trials of endothelin receptor antagonists? | Life sciences 20121015 |
| Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways. | Life sciences 20121015 |
| Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues. | Life sciences 20121015 |
| The combination of theophylline and endothelin receptor antagonism improves exercise performance of rats under simulated high altitude. | Journal of applied physiology (Bethesda, Md. : 1985) 20121015 |
| Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan. | Regulatory toxicology and pharmacology : RTP 20121001 |
| An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. | Regulatory toxicology and pharmacology : RTP 20121001 |
| An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats. | Birth defects research. Part B, Developmental and reproductive toxicology 20121001 |
| Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. | Chest 20120101 |
| Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders. | Journal of aging research 20120101 |
| Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan. | BMJ case reports 20120101 |
| Iontophoresis of endothelin receptor antagonists in rats and men. | PloS one 20120101 |
| Pulmonary arterial hypertension: an update. | Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111201 |
| Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic. | The Korean journal of internal medicine 20111201 |
| Macitentan: entry-into-humans study with a new endothelin receptor antagonist. | European journal of clinical pharmacology 20111001 |
| Endothelin receptor antagonists -- their role in pulmonary medicine. | Revue des maladies respiratoires 20111001 |
| Prevention of post-cardiopulmonary bypass acute kidney injury by endothelin A receptor blockade. | Critical care medicine 20110401 |
| Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. | Hypertension (Dallas, Tex. : 1979) 20110401 |
| Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. | Wiener klinische Wochenschrift 20110401 |
| Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. | Internal medicine journal 20110301 |
| Endothelin receptor antagonists as disease modifiers in systemic sclerosis. | Inflammation & allergy drug targets 20110201 |
| Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension. | The European respiratory journal 20110201 |
| Liver toxicity of sitaxentan in pulmonary arterial hypertension. | The European respiratory journal 20110201 |
| Liver toxicity of sitaxentan in pulmonary arterial hypertension. | European heart journal 20110201 |
| Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. | PharmacoEconomics 20110101 |
| Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. | Vascular health and risk management 20110101 |
| Therapeutic strategies in pulmonary hypertension. | Frontiers in pharmacology 20110101 |
| Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. | Respiratory research 20110101 |
| Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe? | Orphanet journal of rare diseases 20110101 |
| Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101 |
| Overview of current therapeutic approaches for pulmonary hypertension. | Pulmonary circulation 20110101 |
| Vascular involvement in systemic sclerosis (scleroderma). | Journal of inflammation research 20110101 |
| Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. | BMC pulmonary medicine 20110101 |
| Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. | European respiratory review : an official journal of the European Respiratory Society 20101201 |
| Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. | Rheumatology (Oxford, England) 20101101 |
| [Causes of selectivity, activation and inhibition. Molecular mechanisms of endothelin-receptor recognition]. | Pharmazie in unserer Zeit 20101101 |
| Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. | International journal of cardiology 20101029 |
| Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. | American journal of physiology. Heart and circulatory physiology 20101001 |
| Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. | Heart, lung & circulation 20101001 |
| Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. | European heart journal 20100901 |
| Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. | Hypertension (Dallas, Tex. : 1979) 20100601 |
| Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. | Canadian journal of physiology and pharmacology 20100601 |
| Long term combination treatment for severe idiopathic pulmonary arterial hypertension. | World journal of cardiology 20100326 |
| The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension. | The European respiratory journal 20100201 |
| [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension]. | Revue des maladies respiratoires 20100201 |
| The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. | British journal of clinical pharmacology 20100101 |
| Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? | BMC cardiovascular disorders 20100101 |
| Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. | Applied health economics and health policy 20100101 |
| The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. | Vascular health and risk management 20100101 |
| [Endothelin receptor antagonists - their role in pulmonary medicine]. | Revue des maladies respiratoires 20091201 |
| Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20091001 |
| Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20091001 |
| [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension]. | Deutsche medizinische Wochenschrift (1946) 20090801 |
| Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. | European journal of clinical investigation 20090601 |
| A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. | European journal of clinical investigation 20090601 |
| Bleeding events in pulmonary arterial hypertension. | European journal of clinical investigation 20090601 |
| Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy? | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20090601 |
| Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. | The European respiratory journal 20090601 |
| Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas. | IDrugs : the investigational drugs journal 20090601 |
| Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. | Journal of the American College of Cardiology 20090303 |
| [Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy]. | Zeitschrift fur Rheumatologie 20090301 |
| Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. | Arthritis and rheumatism 20090201 |
| Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. | Therapeutic advances in respiratory disease 20090201 |
| Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. | Chest 20090101 |
| Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. | Applied health economics and health policy 20090101 |
| Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan). | Dermatology (Basel, Switzerland) 20090101 |
| Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. | Vascular health and risk management 20090101 |
| Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. | Clinical drug investigation 20090101 |
| Integrated care and optimal management of pulmonary arterial hypertension. | Journal of multidisciplinary healthcare 20090101 |
| Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. | Chest 20081001 |
| [Specific drugs for the treatment of pulmonary arterial hypertension - current status]. | Deutsche medizinische Wochenschrift (1946) 20081001 |
| Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. | Vascular health and risk management 20081001 |
| Pulmonary arterial hypertension: on the way to a manageable disease. | Current opinion in investigational drugs (London, England : 2000) 20080901 |
| Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? | European heart journal 20080801 |
| Sitaxsentan sodium for pulmonary hypertension. | Drugs of today (Barcelona, Spain : 1998) 20080801 |
| The management of pulmonary hypertension in children. | Archives of disease in childhood 20080701 |
| Sitaxentan: new drug. Pulmonary hypertension: better to continue to use bosentan. | Prescrire international 20080601 |
| [Systemic sclerosis]. | Medizinische Monatsschrift fur Pharmazeuten 20080501 |
| [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008]. | La Revue de medecine interne 20080401 |
| Pulmonary hypertension: basic concepts and practical management. | The European respiratory journal 20080201 |
| Endothelin receptor antagonists in pulmonary arterial hypertension. | The European respiratory journal 20080201 |
| Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20080201 |
| Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20080101 |
| Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. | Drugs 20080101 |
| Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. | Texas Heart Institute journal 20080101 |
| The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. | British journal of clinical pharmacology 20071201 |
| Selective and mixed endothelin receptor antagonism in cardiovascular disease. | Trends in pharmacological sciences 20071101 |
| Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension. | Pediatric research 20070301 |
| Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. | Clinics in chest medicine 20070301 |
| [Pulmonary hypertension treatment: future prospects]. | Archivos de bronconeumologia 20070301 |
| Sitaxsentan in the management of pulmonary arterial hypertension. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070215 |
| A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. | Vascular health and risk management 20070201 |
| Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. | Expert opinion on pharmacotherapy 20070101 |
| Sitaxsentan for treatment of pulmonary hypertension. | The Annals of pharmacotherapy 20070101 |
| Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20070101 |
| Sitaxentan: in pulmonary arterial hypertension. | Drugs 20070101 |
| Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. | Arthritis research & therapy 20070101 |
| Therapeutic targets in systemic sclerosis. | Arthritis research & therapy 20070101 |
| [Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension]. | Kardiologiia 20070101 |
| [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists]. | Deutsche medizinische Wochenschrift (1946) 20061208 |
| An evidence-based approach to the management of pulmonary arterial hypertension. | Current opinion in cardiology 20060901 |
| Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. | European journal of clinical investigation 20060901 |
| An evidence-based approach to the management of pulmonary arterial hypertension. | Current opinion in cardiology 20060701 |
| Endothelin receptor antagonists. | Pharmacology & therapeutics 20060601 |
| Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. | Journal of the American College of Cardiology 20060516 |
| Pulmonary hypertension in older children: new approaches and therapies. | Paediatric respiratory reviews 20060101 |
| Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. | Nature clinical practice. Rheumatology 20051201 |
| Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension. | Expert review of cardiovascular therapy 20051101 |
| Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. | European journal of heart failure 20051001 |
| Endothelin antagonism in pulmonary arterial hypertension. | Seminars in respiratory and critical care medicine 20050801 |
| Endothelin receptor antagonists for pulmonary arterial hypertension. | The Cochrane database of systematic reviews 20050125 |
| Pulmonary arterial hypertension associated to connective tissue diseases. | Lupus 20050101 |
| Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. | Expert opinion on investigational drugs 20041101 |
| Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. | Chest 20041001 |
| Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. | Journal of medicinal chemistry 20040408 |
| Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension. | American journal of respiratory and critical care medicine 20040215 |
| The endothelin system in pulmonary arterial hypertension. | Cardiovascular research 20040201 |
| [Updated treatment of primary pulmonary hypertension -- the role of endothelin receptor antagonists]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20040101 |
| New hope for patients with pulmonary hypertension: endothelin receptor antagonists: update for the clinical nurse specialist. | Clinical nurse specialist CNS 20040101 |
| Endothelin receptor blockers in cardiovascular disease. | Circulation 20031104 |
| Will endothelin receptor antagonists have a role in heart failure? | The Medical clinics of North America 20030301 |
| High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. | American journal of physiology. Cell physiology 20030201 |
| Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. | Journal of cardiovascular pharmacology and therapeutics 20020101 |
| Emerging medical therapies for pulmonary arterial hypertension. | Progress in cardiovascular diseases 20020101 |
| High-glucose-induced metallothionein expression in endothelial cells: an endothelin-mediated mechanism. | American journal of physiology. Cell physiology 20010901 |
| Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist. | Journal of medicinal chemistry 20010412 |
| Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. | Journal of medicinal chemistry 19970523 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.